Resolves YES if the initial U.S. wholesale acquisition cost (WAC) at launch for ET-600 (desmopressin oral solution) is ≥ $1,000/month, using the first publicly available WAC from a sponsor price announcement or a pricing compendium (e.g., Red Book / Medi-Span). If ET-600 (desmopressin oral solution) does not have an FDA approval for Central diabetes insipidus / AVP-D (as described by sponsor) on or before 2026-03-27, resolves NO. Reference: https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-fda-acceptance-new-drug-1